New combo shows promise for rare blood cancer
Disease control
Not yet recruiting
This study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better than the standard treatment alone for people with advanced NK/T-cell lymphoma, a rare blood cancer. About 40 adults will be randomly assigned to one of two groups. The m…
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC